1. World Health Organization, International Agency for Research on Cancer, Cancer Today. Available at: https://gco.iarc.fr/today/home (accessed 20 June 2021).
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
3. Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43:682–9.
4. National Cancer Institute. Surveillance, Epidemiology, and End Results Program, Myeloma: Recent Trends in SEER Relative Survival Rates, 2000-2018. Available at: https://seer.cancer.gov/explorer/application.html-site=89&data_type=4&graph_type=2&compareBy=sex&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&race=1&age_ range=1&stage=101&survival_interval=5&advopt_precision=1&advopt_show_ci=on&advopt_display=1 (accessed 15 June 2021).
5. US Food and Drug Administration. VELCADE® (bortezomib): prescribing information. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2014/021602s040lbl.pdf (accessed 14 October 2021).